VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Ime in priimek VRTXON

Uvrstitev No.3637

Tržna kapitalizacija $0.00

Popolnoma razredčena tržna kapitalizacija $0.00

Tržni delež %

Volumen trgovanja/tržna kapitalizacija (24h) 18,680,955.51%

Razpoložljivi obtok 3.84400459

Največja ponudba 0

Skupna ponudba 3.84400459

Hitrost kroženja %

Datum izdaje --

Cena, po kateri je bilo sredstvo prvič izdano --

Najvišja vrednost vseh časov 466.35223147502205, 2026-03-26

Najnižja cena 414.92035330237934, 2026-05-05

Javna veriga blokov VRTXON

Uvod Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Panoga

Družbeni mediji

• Twitter

• Uradna spletna stran
• Raziskovalec blokov

Analiza pretoka sredstev

etfindex:mc_etfindex_source Omejitev odgovornosti: Podatke zagotavlja cmc in se ne smejo obravnavati kot naložbeni nasveti.